A new prodrug of gemcitabine, based on the covalent coupling of squalene to gemcitabine (GemSQ), has been designed to enhance the anticancer activity of gemcitabine, a nucleoside analogue active against a wide variety of tumors. In the present study, the feasibility of encapsulating GemSQ into liposomes either PEGylated or non-PEGylated has been investigated. The in vivo anticancer activity of these formulations has been tested on subcutaneous grafted L1210wt leukemia model and compared to that of free gemcitabine. The liposomal GemSQ appears to be a potential delivery system for the effective treatment of tumors.

Download full-text PDF

Source
http://dx.doi.org/10.1039/c0nr00132eDOI Listing

Publication Analysis

Top Keywords

anticancer activity
12
liposomal squalenoyl-gemcitabine
4
squalenoyl-gemcitabine formulation
4
formulation characterization
4
characterization anticancer
4
activity evaluation
4
evaluation prodrug
4
gemcitabine
4
prodrug gemcitabine
4
gemcitabine based
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!